The updated guideline provides clinicians with evidence-based guidance on important topics such as the optimal usage of urate-lowering therapy (ULT), treatment of gout flares, managing lifestyle factors, and other medication recommendations to help them be successful in optimally managing gout in their patients.
“We need to think about for each individual what are the puzzle pieces that should go together to help manage their osteoarthritis,” said Tuhina Neogi, MD, PhD, FRCPC. “There’s no one size fits all for patients.”
Here’s just a sample of the great education that was available during the meeting that took place in Atlanta. Miss a session at this year’s Annual Meeting? 2019 Annual Meeting scientific registrants receive a complimentary 12-month subscription to ACR Beyond On-Demand.
The ACR thanks you for joining your colleagues from around the world and for helping make the meeting a great experience! See you next year in Washington, DC!
Premenopausal osteoporosis presents a particularly complex clinical challenge because it’s not particularly common and there’s no clear indication for treatment in premenopausal women.
The updated guideline recommendations will be available online in December and are expected to be published in print in early 2020.
Polypharmacy scenarios are common in elderly patients. Don’t be afraid to deprescribe, but make sure to monitor afterwards, the speakers at an ACR/ARP Annual Meeting session emphasized.
On Saturday, Nov. 9, the ACR Board of Directors met to discuss current and future initiatives that impact the ACR’s diverse membership and advance rheumatology.
Many guidelines, including the 2017 ACR Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (GIOP), do not recommend anabolic therapy as initial treatment for osteoporosis and GIOP.
Showcasing cutting-edge rheumatology research from around the world, six of the top abstracts submitted for this year’s Annual Meeting were presented during Tuesday’s Plenary III session.